3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
7
Leukemia, Myeloid, Acute
5
Neoplasms
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Fallopian Tube Neoplasms
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm, Residual
1
Mesothelioma, Malignant
1
Leukemia
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Carcinogenesis
1
Brain Neoplasms
1
Interventions
Gemcitabine
157
Cisplatin
116
pembrolizumab
80
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Cystectomy
40
Docetaxel
38
atezolizumab
33
Magnetic Resonance Spectroscopy
31
durvalumab
30
Radiotherapy
29
BCG Vaccine
26
avelumab
24
Specimen Handling
24
Doxorubicin
23
enfortumab vedotin
22
Fluorouracil
20
Cystoscopy
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Filgrastim
14
Transurethral Resection of Bladder
13
Sunitinib
13
Ipilimumab
13
vinflunine
12
5-aminolevulinic acid hexyl ester
12
tremelimumab
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urinary Bladder Neoplasms
×
Monatide (IMS 3015)
×
Clear all
NCT04106115
2024-12-04
DURANCE
University College, London
Phase 1/2
Recruiting
64 enrolled